Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

The Black Book of Psychotropic Dosing and Monitoring.

Schatzberg AF, Charles D.

Psychopharmacol Bull. 2018 Jan 15;48(1):64-153. No abstract available.

PMID:
29382960
2.

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Blier P, Kasper S, Moeller HJ.

Int J Neuropsychopharmacol. 2017 Feb 1;20(2):121-179. doi: 10.1093/ijnp/pyw100.

3.

Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations.

Girardi P, Brugnoli R, Manfredi G, Sani G.

Drugs R D. 2016 Dec;16(4):293-302. Review.

4.

Hospital treatment, mortality and healthcare costs in relation to socioeconomic status among people with bipolar affective disorder.

Pan YJ, Yeh LL, Chen YC, Kuo KH, Chang CK.

BJPsych Open. 2016 Jan 13;2(1):10-17. eCollection 2016 Jan.

5.

Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA Jr.

Biol Psychiatry. 2017 May 15;81(10):886-897. doi: 10.1016/j.biopsych.2016.05.005. Epub 2016 May 12. Review.

PMID:
27449797
6.

Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort.

Lambert CG, Mazurie AJ, Lauve NR, Hurwitz NG, Young SS, Obenchain RL, Hengartner NW, Perkins DJ, Tohen M, Kerner B.

Bipolar Disord. 2016 May;18(3):247-60. doi: 10.1111/bdi.12391.

8.

Is Valproate Depressogenic in Patients Remitting from Acute Mania? Case Series.

Vasudev K, Sharma P.

Case Rep Psychiatry. 2015;2015:456830. doi: 10.1155/2015/456830. Epub 2015 Nov 17.

9.

Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis.

Strand KB, Chisholm D, Fekadu A, Johansson KA.

Health Policy Plan. 2016 May;31(4):504-13. doi: 10.1093/heapol/czv093. Epub 2015 Oct 21.

10.

Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder.

Dodd S, Fernandes BS, Dean OM.

Curr Neuropharmacol. 2015;13(5):656-62. Review.

11.

Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR.

Int J Bipolar Disord. 2014 Dec 20;2:15. doi: 10.1186/s40345-014-0015-8. eCollection 2014.

12.

Treatment implications of predominant polarity and the polarity index: a comprehensive review.

Carvalho AF, Quevedo J, McIntyre RS, Soeiro-de-Souza MG, Fountoulakis KN, Berk M, Hyphantis TN, Vieta E.

Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu079. doi: 10.1093/ijnp/pyu079. Review.

13.

Bipolar disorder and socioeconomic status: what is the nature of this relationship?

Eid L, Heim K, Doucette S, McCloskey S, Duffy A, Grof P.

Int J Bipolar Disord. 2013 Jun 21;1:9. doi: 10.1186/2194-7511-1-9. eCollection 2013.

14.

The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain.

Maixner DW, Weng HR.

J Pharm Pharmacol (Los Angel). 2013;1(1):001.

15.

Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.

Pan PY, Lee MS, Lo MC, Yang EL, Yeh CB.

BMC Psychiatry. 2014 May 19;14:145. doi: 10.1186/1471-244X-14-145.

16.

Current and emerging therapies for the management of bipolar disorders.

El-Mallakh RS, Elmaadawi AZ, Gao Y, Lohano K, Roberts RJ.

J Cent Nerv Syst Dis. 2011 Aug 7;3:189-97. doi: 10.4137/JCNSD.S4441. Print 2011.

17.

Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder.

Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Wang TY, Yeh TL, Yang YK, Hong JS, Lu RB.

PLoS One. 2013 Jun 27;8(6):e66847. doi: 10.1371/journal.pone.0066847. Print 2013.

18.

Post-acute effectiveness of lithium in pediatric bipolar I disorder.

Findling RL, Kafantaris V, Pavuluri M, McNamara NK, Frazier JA, Sikich L, Kowatch R, Rowles BM, Clemons TE, Taylor-Zapata P.

J Child Adolesc Psychopharmacol. 2013 Mar;23(2):80-90. doi: 10.1089/cap.2012.0063.

19.

Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.

Modi HR, Basselin M, Taha AY, Li LO, Coleman RA, Bialer M, Rapoport SI.

Biochim Biophys Acta. 2013 Apr;1831(4):880-6. doi: 10.1016/j.bbalip.2013.01.008. Epub 2013 Jan 23.

20.

A bivariate mann-whitney approach for unraveling genetic variants and interactions contributing to comorbidity.

Wen Y, Schaid DJ, Lu Q.

Genet Epidemiol. 2013 Apr;37(3):248-55. doi: 10.1002/gepi.21709. Epub 2013 Jan 17.

Supplemental Content

Support Center